

A.

| Cell Line | Organ | Compound  | Low<br>(0.02μM) | Med.<br>(0.2μM) | High<br>(2μM) |
|-----------|-------|-----------|-----------------|-----------------|---------------|
| LN-18     | Brain | Sorafenib | 0.82            | 0.43            | 0.01          |
| LN-18     | Brain | AZ628     | 0.88            | 0.91            | 0.88          |

| Cell Line | Cell viability | NRAS mutation | Tumor type  |
|-----------|----------------|---------------|-------------|
| SK-MEL-30 | 0.18           | Q61K          | Melanoma    |
| IPC-298   | 0.58           | Q61L          | Melanoma    |
| NCI-H2087 | 0.67           | Q61K          | Lung: NSCLC |
| MEL-JUSO  | 0.68           | Q61L          | Melanoma    |
| TYK-nu    | 0.74           | Q61K          | Ovarian     |


  

| Cell Line | Cell viability | NRAS mutation | Tumor type  |
|-----------|----------------|---------------|-------------|
| NCI-H2347 | 0.77           | Q61R          | Lung: NSCLC |
| NCI-H1299 | 0.86           | Q61K          | Lung: NSCLC |
| HMCB      | 0.90           | Q61R          | Melanoma    |

Fraction of Control

- <0.2
- <0.5
- 0.5-0.75
- 0.75-1.5

B.



C.

